Obstructive Jaundice disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OBS001 MIFTS: 54	Obstructive Jaundice Categories: Gastrointestinal diseases, Genetic diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Obstructive Jaundice

MalaCards integrated aliases for Obstructive Jaundice:

Name: Obstructive Jaundice ¹² ¹⁵ ¹⁷

Jaundice, Obstructive ⁴⁵ ⁷⁴

Obstructive Hyperbilirubinemia ¹²

Cholestatic Jaundice Syndrome ¹²

Cholestatic Jaundice ¹²

Jaundice Obstructive ⁵⁶

Jaundice Cholestatic ⁵⁶

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:13603

MeSH ⁴⁵ D041781

NCIt ⁵¹ C34742

SNOMED-CT ⁶⁹ 44018007 59848001

EFO ¹⁷ EFO_1001068

UMLS ⁷⁴ C0022354

Sources

Summaries for Obstructive Jaundice

MalaCards based summary : Obstructive Jaundice, also known as jaundice, obstructive, is related to hepatitis and autoimmune hepatitis, and has symptoms including icterus and jaundice (not of newborn). An important gene associated with Obstructive Jaundice is ALPP (Alkaline Phosphatase, Placental), and among its related pathways/superpathways are Immune response IFN alpha/beta signaling pathway and IL-1 Family Signaling Pathways. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and testes, and related phenotypes are growth/size/body region and homeostasis/metabolism

Sources

Related Diseases for Obstructive Jaundice

Diseases in the Obstructive Jaundice family:

Jaundice, Familial Obstructive, of Infancy

Diseases related to Obstructive Jaundice via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 526)

#	Related Disease	Score	Top Affiliating Genes
1	hepatitis	30.6	F2 GGT1 GPT SLC17A5 TNF
2	autoimmune hepatitis	30.5	F2 GGT1 GPT
3	iga glomerulonephritis	30.4	ALB IL6 REN
4	cholecystitis	30.4	ALB F2 GPT
5	biliary atresia	30.4	ALB GPT HGF
6	acute pancreatitis	30.3	CRP CXCL8 IL6
7	choledocholithiasis	30.1	ALB ALPP F2 GPT SLC17A5
8	acute cholangitis	30.1	CRP IL6
9	viral hepatitis	30.0	ALB F2 GGT1 GPT SLC17A5 TNF
10	portal hypertension	30.0	ALB EDN1 F2 GPT TNF
11	hepatitis e	29.9	ALB F2 GPT TNF
12	bilirubin metabolic disorder	29.9	ALB F2 GGT1 GPT SLC17A5
13	sclerosing cholangitis	29.8	ALB GGT1 GPBAR1 TNF
14	hepatorenal syndrome	29.8	ALB EDN1 F2 REN
15	fascioliasis	29.8	ALB ALPP GPT SLC17A5
16	monocytic leukemia	29.8	CXCL8 IL6 TNF
17	infantile liver failure syndrome 1	29.8	ALB F2 GPT SLC17A5
18	cholestasis	29.7	ALPP F2 GGT1 GPT SLC25A13
19	opisthorchiasis	29.7	CXCL8 GPT TNF
20	abdominal tuberculosis	29.7	ALB CRP F2
21	kawasaki disease	29.6	ALB CRP IL6 TNF
22	biliary tract disease	29.5	ALB F2 GGT1 GPBAR1 SLC25A13
23	cholangitis, primary sclerosing	29.5	ALB GGT1 GPBAR1 GPT
24	hepatic tuberculosis	29.4	ALB ALPP F2 GGT1 GPT
25	alcoholic liver cirrhosis	29.4	ALB CXCL8 F2 SLC17A5
26	lung disease	29.3	CXCL8 EDN1 IL6 TNF
27	acute cystitis	29.3	ALB CRP CXCL8 IL6
28	fatty liver disease	29.3	CXCL8 GGT1 IL6 SLC17A5 TNF
29	hepatitis b	29.2	ALB F2 GGT1 GPT SLC17A5 TNF
30	myeloma, multiple	29.2	ALB CRP CXCL8 HGF IL6 TNF
31	ulcerative colitis	29.2	CRP CXCL8 IL6 TNF
32	gastroenteritis	29.1	ALB CRP CXCL8 IL6 TNF
33	diabetes mellitus	29.1	ALB CRP EDN1 IL6 REN TNF
34	appendicitis	29.1	ALB CRP CXCL8 IL6 TNF
35	cholangitis	29.0	ALB CRP F2 GGT1 GPBAR1 GPT
36	pyelonephritis	28.8	ALB CRP CXCL8 IL6 TNF
37	liver cirrhosis	28.8	ALB EDN1 F2 GGT1 GPT HGF
38	kidney disease	28.8	ALB CRP EDN1 IL6 REN TTR
39	inflammatory bowel disease	28.8	CRP CXCL8 IL6 TNF
40	peritonitis	28.7	ALB CRP CXCL8 F2 IL6 TNF
41	liver disease	28.6	ALB ALPP F2 GGT1 GPT HGF
42	malaria	28.4	ALB CRP CXCL8 EDN1 IL6 TNF
43	mirizzi syndrome	11.4
44	biliary malformation with renal tubular insufficiency	11.4
45	cholestasis, benign recurrent intrahepatic, 1	11.3
46	acth deficiency, isolated	11.2
47	cholestasis, benign recurrent intrahepatic, 2	11.2
48	bile acid synthesis defect, congenital, 1	11.2
49	congenital disorder of glycosylation, type ik	11.2
50	pancreatitis	10.6

Graphical network of the top 20 diseases related to Obstructive Jaundice:

Sources

Symptoms & Phenotypes for Obstructive Jaundice

UMLS symptoms related to Obstructive Jaundice:

icterus, jaundice (not of newborn)

MGI Mouse Phenotypes related to Obstructive Jaundice:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	9.85	EDN1 F2 GGT1 GPBAR1 HGF IL6
2	homeostasis/metabolism	MP:0005376	9.73	ALB CRP EDN1 F2 GGT1 GPBAR1
3	renal/urinary system	MP:0005367	9.23	ALB EDN1 GGT1 GPBAR1 IL6 REN

Sources

Drugs & Therapeutics for Obstructive Jaundice

Drugs for Obstructive Jaundice (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ceftriaxone

Approved

Phase 4

73384-59-5

5479530 5361919

Lactulose

Approved

Phase 4

4618-18-2

11333

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Anti-Bacterial Agents

Phase 4,Not Applicable

Anti-Infective Agents

Phase 4,Not Applicable

Cytochrome P-450 CYP1A2 Inhibitors

Phase 4

Topoisomerase Inhibitors

Phase 4

Antibiotics, Antitubercular

Phase 4,Not Applicable

Anti-Infective Agents, Urinary

Phase 4

Antitubercular Agents

Phase 4

Renal Agents

Phase 4

Trioxsalen

Approved

Phase 2, Phase 3,Not Applicable

3902-71-4

5585

Ezetimibe

Approved

Phase 3

163222-33-1

150311

Atorvastatin

Approved

Phase 3

134523-00-5

60823

Nicotinamide

Approved, Investigational

Phase 3

98-92-0

936

Simvastatin

Approved

Phase 3

79902-63-9

54454

Calcium

Approved, Nutraceutical

Phase 3

7440-70-2

271

Niacin

Approved, Investigational, Nutraceutical

Phase 3

59-67-6

938

Methionine

Approved, Nutraceutical

Phase 3

63-68-3

6137

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Dihematoporphyrin Ether

Phase 2, Phase 3,Not Applicable

Hematoporphyrin Derivative

Phase 2, Phase 3,Not Applicable

Lipid Regulating Agents

Phase 3

Anticholesteremic Agents

Phase 3

Hypolipidemic Agents

Phase 3

Antimetabolites

Phase 3

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 3

Calcium, Dietary

Phase 3

Rosuvastatin Calcium

Phase 3

147098-20-2

Nicotinic Acids

Phase 3

Vitamin B3

Phase 3

Vitamins

Phase 3

Vasodilator Agents

Phase 3

Vitamin B Complex

Phase 3

Nutrients

Phase 3

Trace Elements

Phase 3

Micronutrients

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Pharmaceutical Solutions

Phase 3

Ursodeoxycholic acid

Approved, Investigational

Phase 2

128-13-2

31401

Neostigmine

Approved, Vet_approved

Phase 1, Phase 2

59-99-4

4456

Pancrelipase

Approved, Investigational

Phase 2,Phase 1

53608-75-6

Gastrointestinal Agents

Phase 2

Liver Extracts

Phase 2,Phase 1

Cholagogues and Choleretics

Phase 2

Peripheral Nervous System Agents

Phase 1, Phase 2

Anti-Inflammatory Agents

Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 62)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice	Unknown status	NCT00731419	Phase 4
2	Antibiotics to Decrease Post ERCP Cholangitis	Unknown status	NCT03087656	Phase 4	Ceftriaxone;Levofloxacin
3	Human Kidney Histopathology in Obstructive Jaundice	Completed	NCT01090193	Phase 4
4	Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents	Completed	NCT01315522	Phase 4
5	Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice	Unknown status	NCT01744938	Phase 3
6	Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma	Unknown status	NCT01755013	Phase 2, Phase 3
7	Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.	Completed	NCT00391183	Phase 2, Phase 3
8	A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Completed	NCT02550288	Phase 3	Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule
9	A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)	Completed	NCT02460159	Phase 3	EZ 10 mg/Atorva 20 mg FDC;EZ 10 mg/Atorva 10 mg FDC
10	A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)	Completed	NCT02741245	Phase 3	Ezetimibe 10 mg;Rosuvastatin 2.5 mg;Placebo for Ezetimibe;Placebo for Rosuvastatin
11	MK-0524B Lipid Study (MK-0524B-063)	Completed	NCT00479882	Phase 3	Comparator: simvastatin;MK-0524A;Placebo;MK-0524B
12	Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)	Completed	NCT00289900	Phase 3	MK-0524A;Atorvastatin;Simvastatin
13	Remaxol® in Mechanical Jaundice of Non-malignant Origin	Recruiting	NCT03418935	Phase 3	Remaxol (succinate + methionine + inosine + nicotinamide);Ringer's Solution
14	Remaxol® in Malignant Mechanical Jaundice	Recruiting	NCT03416062	Phase 3	Remaxol®;Ringer's Solution
15	A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)	Terminated	NCT01294683	Phase 3	Simvastatin;Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM);Extended Release (ER) niacin/laropiprant (N/LRPT);Placebo
16	Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction	Withdrawn	NCT01622803	Phase 3
17	The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice	Unknown status	NCT01688375	Phase 2	Ursodeoxycholic Acid
18	Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice	Unknown status	NCT01275768	Phase 1, Phase 2
19	Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation.	Unknown status	NCT02279147	Phase 1, Phase 2	neostigmine methylsulfate，raceanisodamine hydrochloride
20	Evaluation of Preoperative Biliary Drainage Before Pancreatoduodenectomy	Unknown status	NCT01941342	Phase 2
21	Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors.	Completed	NCT02166840	Phase 2
22	Radiofrequency Ablation for Biliopancreatic Malignancy	Completed	NCT02468076	Phase 2
23	SMOFlipid to Lessen the Severity of Neonatal Cholestasis	Terminated	NCT02721277	Phase 1, Phase 2	SMOFlipid
24	C-VISA BikDD: Liposome in Advanced Pancreatic Cancer	Withdrawn	NCT00968604	Phase 1
25	Immune Function in Patients With Obstructive Jaundice	Unknown status	NCT01367821
26	Cholangioscopic Assessment of Occluded Biliary Stent and Role of Biliary Radiofrequency Ablation	Unknown status	NCT03133026	Not Applicable
27	Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage	Unknown status	NCT01686425	Not Applicable
28	Study of Abdominal Drainage in LCBDE+PC	Unknown status	NCT03120754	Not Applicable
29	Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis	Unknown status	NCT02841800	Not Applicable
30	Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice	Unknown status	NCT00155194
31	Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders	Unknown status	NCT01438385
32	Application of n-3 Fatty to Patient of Jaundice	Completed	NCT03376945		trail cohort;control cohort
33	Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers	Completed	NCT01134276	Not Applicable
34	Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma	Completed	NCT01506115	Not Applicable	Photofrin
35	Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer	Completed	NCT00409864	Not Applicable
36	Outcome of Carbon Dioxide Versus Air Insufflations During Endoscopic Retrograde Cholangiopancreatography (ERCP)	Completed	NCT01321203
37	Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP	Completed	NCT03510754
38	Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)	Completed	NCT00196105	Not Applicable
39	Biliary Atresia, Hepatic Buffer Response and Sevoflurane	Completed	NCT02471209		Sevoflurane
40	Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones	Completed	NCT02460315	Not Applicable
41	Endoscopic Retrograde Cholangiopancreatography (ERCP) Based Sampling of Indeterminate Bile Duct Strictures	Completed	NCT01580709	Not Applicable
42	Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation	Completed	NCT02477228	Not Applicable
43	Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance	Recruiting	NCT03406676	Not Applicable	Methylene Blue
44	EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice	Recruiting	NCT03494023
45	Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression	Recruiting	NCT01191814	Not Applicable
46	Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction	Recruiting	NCT02937246	Not Applicable
47	RFA RCT for Pancreatic or Bile Duct Cancer	Recruiting	NCT02166190	Not Applicable
48	The Necessity of Bile Cultures in Patients With Acute Cholangitis	Recruiting	NCT02601417	Not Applicable
49	A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction	Recruiting	NCT02659852	Not Applicable
50	Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study	Recruiting	NCT02646514	Not Applicable

Search NIH Clinical Center for Obstructive Jaundice

Cochrane evidence based reviews: jaundice, obstructive

Sources

Genetic Tests for Obstructive Jaundice

Sources

Anatomical Context for Obstructive Jaundice

MalaCards organs/tissues related to Obstructive Jaundice:

⁴²

Liver, Pancreas, Testes, Lung, Kidney, Neutrophil, Breast

Sources

Publications for Obstructive Jaundice

Articles related to Obstructive Jaundice:

(show top 50) (show all 2293)

#	Title	Authors	Year
1	Peri-Ampullary Metastasis From Endometrial Adenocarcinoma: A Rare Etiology of Obstructive Jaundice. ( 30834033 )	Ahmmad E...Dirweesh A	2019
2	Clonorchiasis sinensis detected by laparoscopic exploration of biliary tracts in two patients with obstructive jaundice. ( 30621611 )	Liu X...Li J	2019
3	Duodenal somatostatinoma presenting as obstructive jaundice with the coexistence of a gastrointestinal stromal tumour in neurofibromatosis type 1: a case with review of the literature. ( 30635305 )	Thavaraputta S...Lado-Abeal J	2019
4	First report of hepatobiliary Mycobacterium avium infection developing obstructive jaundice in a patient with neutralizing anti-interferon-gamma autoantibodies. ( 30505452 )	Namkoong H...Hasegawa N	2019
5	Safety of Percutaneous Transhepatic Biliary Stenting in Patients with Obstructive Jaundice. ( 30630564 )	Khan R...Fiaz AB	2019
6	The Application of Intravoxel Incoherent Motion Diffusion-Weighted Imaging in the Diagnosis of Hilar Obstructive Jaundice. ( 30664118 )	Xu X...Zhang X	2019
7	Huge Intramural Duodenal Hematoma Complicated with Obstructive Jaundice following Endoscopic Hemostasis. ( 30690957 )	Kim HS...Cho JY	2019
8	Biliary ascariasis - an unusual case of obstructive jaundice. ( 30710698 )	Mohd Noor NA...Tan CH	2019
9	Bile Cast Nephropathy in a Patient With Obstructive Jaundice. ( 30775631 )	Chan S...Wolley MJ	2019
10	A Case of Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )	Hamamoto H....Ido A.	2018
11	Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )	Blouhos K....Hatzigeorgiadis A.	2018
12	Efficacy of<sup>125</sup>I Versus Non-<sup>125</sup>I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice. ( 29305738 )	Li S....Wang W.	2018
13	A Surgically Resected Pancreatic Schwannoma with Obstructive Jaundice with Special Reference to Differential Diagnosis from Other Cystic Lesions in the Pancreas. ( 29606941 )	Watanabe T....Shirabe K.	2018
14	Hepatobiliary and Pancreatic: Rare cause of obstructive jaundice by Trichosporon asahii. ( 29372610 )	Zhang L.H....Tang C.W.	2018
15	A Systematic Review and Meta-analysis of Intraluminal Brachytherapy Versus Stent Alone in the Treatment of Malignant Obstructive Jaundice. ( 29075881 )	Xu X....Ji W.	2018
16	A patient with abdominal pain and obstructive jaundice. ( 29749334 )	Dindar G....Turgut H.T.	2018
17	Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice. ( 29767833 )	Tong D.P....Li Y.	2018
18	Elevated endogenous opioids in obstructive jaundice: The possible skin mechanisms. ( 29857894 )	Li X....Tao K.	2018
19	MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. ( 29105510 )	Huang Y.H....Wang F.S.	2018
20	Spontaneous remission of obstructive jaundice in rats: Selection of experimental models. ( 29904412 )	Lv Y....Li Y.	2018
21	Pancreatic Burkitt's lymphoma presenting as an unusual cause of obstructive jaundice. ( 29696783 )	Yoshizawa N....Takei Y.	2018
22	Bile and circulating HMGB1 contributes to systemic inflammation in obstructive jaundice. ( 29907203 )	Yang R....Tonnessen T.I.	2018
23	Obstructive jaundice caused by an adenoma of the common hepatic duct. ( 29980303 )	Curieses Luengo M....A8lvarez A8lvarez A.	2018
24	MicroRNA-29a mitigation of toll-like receptor 2 and 4 signaling and alleviation of obstructive jaundice-induced fibrosis in mice. ( 29366780 )	Lin Y.C....Huang Y.H.	2018
25	Combined Effectiveness of Honey and Immunonutrition on Bacterial Translocation Secondary to Obstructive Jaundice in Rats: Experimental Study. ( 29786675 )	Oguz S....Erenoglu C.	2018
26	Primary pancreatic lymphoma as a cause of obstructive jaundice. ( 29615287 )	RodrA-guez-Infante A....GarcA-a-FlA^rez L.J.	2018
27	Pancreatobiliary fistula associated with intraductal papillary mucinous carcinoma accompanying obstructive jaundice: A case report. ( 29890488 )	Komo T....Hirabayashi N.	2018
28	The Effect of Calcium Dobesilate on Liver Damage in Experimental Obstructive Jaundice. ( 29589984 )	Unal Y....Hucumenoglu S.	2018
29	Duodenal mucinous adenocarcinoma presenting as ileus, obstructive jaundice and massive ascites: A case report. ( 29456851 )	Ding D....Zhang S.	2018
30	Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features. ( 29748084 )	Ma J....Yan Z.	2018
31	Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression. ( 29882088 )	Kong E.L....Wu F.X.	2018
32	Comparison of Endoscopic Ultrasonography Guided Biliary Drainage and Percutaneous Transhepatic Biliary Drainage in the Management of Malignant Obstructive Jaundice After Failed ERCP: Erratum. ( 29613967 )		2018
33	Pathophysiological consequences of obstructive jaundice and perioperative management. ( 29428098 )	Pavlidis E.T....Pavlidis T.E.	2018
34	Adenosquamous Carcinoma of the Ampulla of Vater: A Rare Cause of Obstructive Jaundice. ( 29998166 )	Carvalho L...Chagas C	2018
35	Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma. ( 30057125 )	Martin EK...Martin RCG	2018
36	Immunoglobulin G4 Sclerosing Cholangitis: An Unusual Cause of Obstructive Jaundice-Case Report and Literature Review. ( 30210896 )	Shrestha P...Karmacharya P	2018
37	EUS-guided versus percutaneous biliary access in patients with obstructive jaundice due to gastric cancer. ( 30327252 )	Ogura T...Higuchi K	2018
38	Obstructive Jaundice due to Pancreatic Involvement as an Initial Presentation of Adult Acute Lymphoblastic Leukemia. ( 30627461 )	Oladiran O...Nwosu I	2018
39	Obstructive jaundice caused by myeloid sarcoma in duodenal ampulla. ( 30253977 )	Li X...Li Y	2018
40	Obstructive Jaundice due to Primary Neurofibroma of the Common Bile Duct. ( 30606373 )	Xiaohua L...Yong L	2018
41	Treatment of pancreatic head cancer with obstructive jaundice by endoscopy ultrasonography-guided gastrojejunostomy: A case report and literature review. ( 29995808 )	Shen Z...Wang X	2018
42	Safety and efficacy of n-3 fatty acid-based parenteral nutrition in patients with obstructive jaundice: a propensity-matched study. ( 30006616 )	Gong Q...Chen XP	2018
43	Obstructive Jaundice in a Patient with Polycystic Liver. ( 30013762 )	Khoonsari M...Vafaeimanesh J	2018
44	Effect of sildenafil citrate on the liver structure and function in obstructive jaundice: An experimental study. ( 30023974 )	?im?ek T...?ahin M	2018
45	A Rare Cause of Obstructive Jaundice: Cecal Herniation through the Foramen of Winslow. ( 30034928 )	Welaratne I...Nasoodi A	2018
46	Afferent loop obstruction with obstructive jaundice and ileus due to an enterolith after distal gastrectomy: A case report. ( 30064120 )	Sato K...Ohdan H	2018
47	A Case of Obstructive Jaundice Caused by Metastasis of Ovarian Cancer to the Duodenal Major Papilla. ( 30090022 )	Takasaki Y...Hojo H	2018
48	Acute paracoccidioidomycosis with duodenal and cutaneous involvement and obstructive jaundice. ( 30148057 )	Bernardes Filho F...Towersey L	2018
49	Selection of biliary decompression method for treatment of obstructive jaundice in patients of older age groups. ( 30176629 )	Kanikovskyi OY...Shaprynskyi YV	2018
50	Preserving hepatic artery flow during portal triad blood occlusion improves regeneration of the remnant liver in rats with obstructive jaundice following partial hepatectomy. ( 30186418 )	Kong Z...Dong JH	2018

Sources

Genes for Obstructive Jaundice

Genes related to Obstructive Jaundice (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ALPP	Alkaline Phosphatase, Placental	Protein Coding	29.69	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15625352 1995758 15813880
2	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	28.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1721943
3	SLC25A13	Solute Carrier Family 25 Member 13	Protein Coding	25.2	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶	12692712 11343052
4	TTR	Transthyretin	Protein Coding	23.96	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11702667
5	ALB	Albumin	Protein Coding	23.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	GGT1	Gamma-Glutamyltransferase 1	Protein Coding	23.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18773671 19143075
7	IL6	Interleukin 6	Protein Coding	22.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	TNF	Tumor Necrosis Factor	Protein Coding	22.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	F2	Coagulation Factor II, Thrombin	Protein Coding	22.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	SLC17A5	Solute Carrier Family 17 Member 5	Protein Coding	21.78	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15625352 2342668
11	EDN1	Endothelin 1	Protein Coding	21.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	REN	Renin	Protein Coding	20.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	HGF	Hepatocyte Growth Factor	Protein Coding	20.65	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	GPBAR1	G Protein-Coupled Bile Acid Receptor 1	Protein Coding	20.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	20.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	CRP	C-Reactive Protein	Protein Coding	20.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Obstructive Jaundice

Sources

Expression for Obstructive Jaundice

Search GEO for disease gene expression data for Obstructive Jaundice.

Sources

Pathways for Obstructive Jaundice

Pathways related to Obstructive Jaundice according to GeneCards Suite gene sharing:

(show all 19)

#	Super pathways	Score	Top Affiliating Genes
1	Immune response IFN alpha/beta signaling pathway ²³ Show member pathways Cytokine Network ⁶⁵ Interferon alpha/beta signaling ⁶⁷ Regulation of IFNA signaling ⁶⁷	12.09	CXCL8 HGF IL6 TNF
2	IL-1 Family Signaling Pathways ⁶⁶ Show member pathways Immune response IL-1 signaling pathway ²³ Mucin expression in CF via TLRs, EGFR signaling pathways ²³	12	CXCL8 EDN1 IL6 TNF
3	Selenium Micronutrient Network ¹ Show member pathways Folate Metabolism ¹ Metabolism of ingested MeSeO2H into MeSeH ⁶⁷ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	11.97	ALB CRP F2 GGT1 IL6 TNF
4	Spinal Cord Injury ¹	11.84	CXCL8 IL6 TNF
5	Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁶	11.83	ALB ALPP HGF IL6
6	TNF signaling pathway ³⁸	11.78	EDN1 IL6 TNF
7	Interleukin-4 and 13 signaling ⁶⁷	11.73	CXCL8 HGF IL6 TNF
8	Amoebiasis ³⁸	11.72	CXCL8 IL6 TNF
9	Rheumatoid arthritis ³⁸	11.68	CXCL8 IL6 TNF
10	AGE-RAGE signaling pathway in diabetic complications ³⁸	11.62	CXCL8 EDN1 IL6 TNF
11	Pertussis ³⁸	11.59	CXCL8 IL6 TNF
12	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²³	11.5	CXCL8 IL6 TNF
13	Legionellosis ³⁸	11.43	CXCL8 IL6 TNF
14	Interleukin-10 signaling ⁶⁷	11.34	CXCL8 IL6 TNF
15	FOXA2 and FOXA3 transcription factor networks ¹	11.25	ALB F2 TTR
16	Malaria ³⁸	11.25	CXCL8 HGF IL6 TNF
17	G-protein signaling_RhoB regulation pathway ²³	11.03	CXCL8 HGF IL6 TNF
18	Lung fibrosis ¹	10.82	CXCL8 EDN1 HGF IL6 TNF
19	Overview of nanoparticle effects ¹	10.54	CRP CXCL8 IL6 TNF

Sources

GO Terms for Obstructive Jaundice

Cellular components related to Obstructive Jaundice according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.65	ALB CRP CXCL8 EDN1 F2 HGF
2	extracellular space	GO:0005615	9.4	ALB CRP CXCL8 EDN1 F2 GGT1

Biological processes related to Obstructive Jaundice according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	9.73	CXCL8 HGF IL6 TNF
2	cellular protein metabolic process	GO:0044267	9.67	ALB F2 IL6 TTR
3	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.65	EDN1 IL6 TNF
4	defense response to Gram-positive bacterium	GO:0050830	9.63	CRP IL6 TNF
5	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.58	F2 HGF TNF
6	embryonic digestive tract development	GO:0048566	9.51	CXCL8 TNF
7	positive regulation of glial cell proliferation	GO:0060252	9.49	IL6 TNF
8	positive regulation of smooth muscle cell proliferation	GO:0048661	9.43	EDN1 IL6 TNF
9	acute-phase response	GO:0006953	9.33	CRP F2 IL6
10	positive regulation of neuroinflammatory response	GO:0150078	9.32	IL6 TNF
11	regulation of signaling receptor activity	GO:0010469	9.17	CXCL8 EDN1 F2 HGF IL6 TNF
12	negative regulation of lipid storage	GO:0010888	9.13	CRP IL6 TNF

Molecular functions related to Obstructive Jaundice according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.43	ALB CRP HGF SLC25A13 TNF TTR
2	cytokine activity	GO:0005125	8.92	CXCL8 EDN1 IL6 TNF

Sources

Sources for Obstructive Jaundice

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia